HK1038040A1 - Non-endogenous, constitutively activated human g protein-coupled receptors - Google Patents

Non-endogenous, constitutively activated human g protein-coupled receptors

Info

Publication number
HK1038040A1
HK1038040A1 HK01108940A HK01108940A HK1038040A1 HK 1038040 A1 HK1038040 A1 HK 1038040A1 HK 01108940 A HK01108940 A HK 01108940A HK 01108940 A HK01108940 A HK 01108940A HK 1038040 A1 HK1038040 A1 HK 1038040A1
Authority
HK
Hong Kong
Prior art keywords
endogenous
sub
sup
codon
gpcr
Prior art date
Application number
HK01108940A
Other languages
English (en)
Inventor
Dominic P Behan
Derek T Chalmers
Chen W Liaw
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of HK1038040A1 publication Critical patent/HK1038040A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK01108940A 1998-10-13 2001-12-20 Non-endogenous, constitutively activated human g protein-coupled receptors HK1038040A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/170,496 US6555339B1 (en) 1997-04-14 1998-10-13 Non-endogenous, constitutively activated human protein-coupled receptors
PCT/US1999/023938 WO2000022129A1 (en) 1998-10-13 1999-10-12 Non-endogenous, constitutively activated human g protein-coupled receptors

Publications (1)

Publication Number Publication Date
HK1038040A1 true HK1038040A1 (en) 2002-03-01

Family

ID=22620080

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01108940A HK1038040A1 (en) 1998-10-13 2001-12-20 Non-endogenous, constitutively activated human g protein-coupled receptors

Country Status (15)

Country Link
US (2) US6555339B1 (da)
EP (1) EP1121431B9 (da)
JP (2) JP4672866B2 (da)
KR (1) KR100598752B1 (da)
CN (1) CN1329511C (da)
AT (1) ATE318311T1 (da)
AU (5) AU769987B2 (da)
CA (1) CA2342314A1 (da)
DE (3) DE69929993D1 (da)
DK (1) DK1121431T5 (da)
ES (1) ES2163384T3 (da)
HK (1) HK1038040A1 (da)
IL (2) IL141965A0 (da)
NZ (1) NZ510331A (da)
WO (2) WO2000022129A1 (da)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO2000031258A2 (en) * 1998-11-20 2000-06-02 Arena Pharmaceuticals, Inc. Human orphan g protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
GB9903767D0 (en) * 1999-02-18 1999-04-14 Univ Glasgow Receptor assay
EP1235931A2 (en) * 1999-07-30 2002-09-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for prognostication, diagnosis, prevention, and treatment of bone-related disorders and other disorders
JP4768946B2 (ja) * 1999-11-17 2011-09-07 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒトｇタンパク質共役型受容体の内因性および非内因性型
AU5787901A (en) * 1999-12-10 2001-07-09 Astrazeneca Ab Compound
JP2003517008A (ja) * 1999-12-17 2003-05-20 アストラゼネカ アクチボラグ 新規化合物
GB0003898D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
GB0003902D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
WO2001061359A2 (en) * 2000-02-18 2001-08-23 Glaxo Group Limited Identification of modulators of gpr41 or gpr42 activity
AU2001241778A1 (en) * 2000-02-29 2001-09-12 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of cardiovascular, hepatic, and bone disease
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU7048901A (en) * 2000-04-26 2001-11-07 Aventis Pharma Gmbh Edg8 receptor, its preparation and use
EP1149907A1 (en) * 2000-04-26 2001-10-31 Aventis Pharma Deutschland GmbH EDG8 receptor, its preparation and use
AU2001250536A1 (en) * 2000-05-03 2001-11-12 Astrazeneca Ab Methods
WO2001096567A1 (fr) * 2000-06-15 2001-12-20 Takeda Chemical Industries, Ltd. Nouvelle proteine receptrice couplee a la proteine g et adn de ce recepteur
AU2001268471A1 (en) * 2000-06-16 2002-01-02 Incyte Genomics, Inc. G-protein coupled receptors
CA2413195C (en) * 2000-06-21 2012-01-17 Takeda Chemical Industries, Ltd. Ligand to gpr8 and dna thereof
AU2001267898A1 (en) * 2000-07-04 2002-01-14 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
AU2002212140A1 (en) * 2000-08-18 2002-02-25 Novartis Ag Inflammation related g-protein coupled receptor
AU2001286945A1 (en) * 2000-08-30 2002-03-13 John Hopkins University School Of Medicine Identification of activated receptors and ion channels
AU2000276780A1 (en) * 2000-10-02 2001-04-23 Biofocus Discovery Limited Cellular receptor mutations predicted by multiple-sequence-allignment
WO2002044368A1 (fr) * 2000-11-30 2002-06-06 Takeda Chemical Industries, Ltd. Nouvelles proteines du recepteur couple a la proteine g et leurs adn
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
EP1412372A4 (en) * 2001-02-26 2005-08-24 Arena Pharm Inc ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G-PROTEIN COUPLED RECEPTORS
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US6919176B2 (en) 2001-05-07 2005-07-19 Amgen Inc. Polypeptides and nucleic acids associated with cancer
WO2002093161A1 (fr) * 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Methode de balayage
US20020177190A1 (en) * 2001-05-24 2002-11-28 Yanbin Liang Recombinant simian GPR3 receptor
AU2002310326A1 (en) * 2001-06-05 2002-12-23 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated versions of plant g protein-coupled receptor: gcr1
JP2003018992A (ja) * 2001-06-28 2003-01-21 Inst Of Physical & Chemical Res Ｐａｅｌ受容体、Ｐａｅｌ受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
CA2452867A1 (en) * 2001-07-13 2003-01-23 Akzo Nobel N.V. Allelic variants of gpr50
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
JP2005507673A (ja) * 2001-11-05 2005-03-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １３９、２５８、１２６１、１４８６、２３９８、２４１４、７６６０、８５８７、１０１８３、１０５５０、１２６８０、１７９２１、３２２４８、６０４８９または９３８０４を用いる心血管疾患を治療するための方法および組成物
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
EP1463759B8 (en) 2002-01-07 2013-07-10 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
EP1336655A1 (en) * 2002-01-12 2003-08-20 Aventis Pharma Deutschland GmbH Method of identifying protein CAMS (constitutively active mutants)
WO2003062396A2 (en) * 2002-01-23 2003-07-31 Arena Pharmaceuticals, Inc. Non-endogenous versions of human g protein-coupled receptor: fshr
WO2003066077A2 (en) * 2002-02-06 2003-08-14 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
AU2003211952A1 (en) 2002-02-14 2003-09-04 Takeda Chemical Industries, Ltd. Novel screening method
WO2003078602A2 (en) * 2002-03-15 2003-09-25 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
WO2003104381A2 (en) * 2002-06-08 2003-12-18 Astrazeneca Ab Methods
WO2004013285A2 (en) * 2002-08-01 2004-02-12 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
WO2004015427A2 (en) * 2002-08-06 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
AU2003251471A1 (en) * 2002-08-06 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
US20060239999A1 (en) * 2002-08-22 2006-10-26 Mayumi Saki Preventive and/or therapeutic drugs for asthma
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7056685B1 (en) * 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
PL376659A1 (pl) 2002-11-06 2006-01-09 Tularik Inc. Skondensowane związki heterocykliczne
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
AU2003297644A1 (en) * 2002-12-04 2004-06-23 Synaptic Pharmaceutical Corporation Uses of the snorf55 receptor
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7427487B2 (en) * 2003-03-18 2008-09-23 Arena Pharmaceuticals, Inc. Constitutively active CXCR3 G protein-coupled chemokine receptor and modulators thereof for the treatment of inflammatory disorders
JPWO2004093912A1 (ja) * 2003-04-23 2006-07-13 協和醗酵工業株式会社 好中球性炎症疾患の予防および／または治療剤
US20080009551A1 (en) * 2003-04-30 2008-01-10 Arena Pharmaceuticals, Inc. Methods and Compositions for Identifying Modulators of G Protein-Coupled Receptors
US7405053B2 (en) * 2003-05-20 2008-07-29 The University Court Of The University Of Glasgow Materials and methods relating to G-protein coupled receptor oligomers
US7625696B2 (en) * 2003-09-11 2009-12-01 Takeda Pharmaceutical Company Limited Screening method
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
CA2544611A1 (en) * 2003-10-09 2005-04-21 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
WO2005040829A2 (en) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005040211A2 (en) * 2003-10-23 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005040828A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005040825A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
EP3120861B1 (en) 2003-11-06 2018-08-15 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
AU2004315111B2 (en) * 2004-01-29 2010-03-04 Cellzome Ag Treatment of neurodegenerative diseases by the use of GPR49
AU2005216878B2 (en) 2004-02-20 2010-06-17 Aventis Pharmaceuticals Inc. Oxydecahydronaphthalene modulators of HM74
WO2005101005A1 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 32 (gpr32)
ATE486962T1 (de) * 2004-04-27 2010-11-15 Takeda Pharmaceutical Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
GB0508988D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
US8429755B2 (en) 2005-05-26 2013-04-23 Sandisk Technologies Inc. System and method for receiving digital content
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
AU2006304329A1 (en) * 2005-10-14 2007-04-26 Arena Pharmaceuticals, Inc. GPR22 and methods relating thereto
US7998685B2 (en) * 2005-11-10 2011-08-16 Arena Pharmaceuticals, Inc. Methods of identifying candidate compounds of the human G protein-coupled receptor, GPR50, as modulators of body mass or adiposity
US8785135B2 (en) * 2007-03-22 2014-07-22 Heptares Therapeutics Limited Mutant G-protein coupled receptors and methods for selecting them
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2010091692A2 (en) * 2009-04-30 2010-08-19 H. Lundbeck A/S Constitutively active mutants and uses thereof
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
RS52983B (en) 2010-04-15 2014-02-28 Spirogen Sárl PIROLOBENZODIAZEPINI I NJIHOVI conjugated
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
JP5804341B2 (ja) * 2010-08-06 2015-11-04 国立大学法人山口大学 エストロゲン関連疾患の判定方法
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
KR101992502B1 (ko) 2011-05-12 2019-06-24 제넨테크, 인크. 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
EP2750713B1 (en) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
WO2014057117A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
ES2649990T3 (es) 2012-10-12 2018-01-16 Medimmune Limited Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
US9931415B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SI2766048T1 (sl) 2012-10-12 2015-03-31 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
HUE041274T2 (hu) 2012-10-12 2019-05-28 Adc Therapeutics Sa Pirrolobenzodiazepin-anti-PSMA-antitest konjugátumok
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
CN105307685B (zh) 2013-03-13 2019-03-08 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
MX2016001020A (es) 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
US9340582B2 (en) 2013-07-25 2016-05-17 Novartis Ag Bioconjugates of synthetic apelin polypeptides
KR20160042080A (ko) 2013-08-12 2016-04-18 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
SG11201604905WA (en) 2013-12-16 2016-07-28 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
EP3134433A4 (en) 2014-04-25 2017-10-04 Libramen Naturals Inc. G-protein coupled receptor 22 transformed cell lines and uses therefor
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
AU2015314826A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
MX2017003523A (es) 2014-09-17 2017-11-08 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
KR20170101895A (ko) 2014-11-25 2017-09-06 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 접합체
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017140803A1 (en) 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
WO2017140793A1 (en) 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3544636T (pt) 2017-02-08 2021-05-04 Medimmune Ltd Conjugados de anticorpos-pirrolobenzodiazepinas
ES2926144T3 (es) 2017-04-18 2022-10-24 Medimmune Ltd Conjugados de pirrolobenzodiazepina
MX2019012464A (es) 2017-04-20 2019-12-11 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
RS62928B1 (sr) 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
RU2020113749A (ru) 2017-09-20 2021-10-20 пиЭйч ФАРМА Ко., ЛТД. Аналоги таиланстатина
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
IL296050B1 (en) * 2018-08-01 2024-08-01 Immunitybio Inc A quadricistronic system containing a receptor or cytokine and a chimeric antigen receptor for genetic modification of immunotherapies
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (zh) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 缀合的化学降解诱导剂及使用方法
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114848822A (zh) * 2022-06-01 2022-08-05 合肥工业大学 Gpr31抑制剂在制备预防和治疗血管钙化药物中的应用
WO2024044659A1 (en) * 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE220421T1 (de) 1990-02-26 2002-07-15 Univ Leland Stanford Junior Identifizierung und expression von insekten- steroidrezeptor-dns-sequenzen
JPH06511386A (ja) 1991-10-01 1994-12-22 アメリカ合衆国 リガンドおよびリガンドのアンタゴニストを同定する方法
ATE365209T1 (de) * 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
CA2145182C (en) 1992-09-25 2001-09-18 Jonathan A. Bard Dna encoding human alpha 1 adrenergic receptors and uses thereof
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
AU1173995A (en) 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
WO1995018380A1 (en) * 1993-12-30 1995-07-06 The Salk Institute For Biological Studies Novel uses for gal4-receptor constructs
US5573944A (en) 1994-07-22 1996-11-12 President And Fellows Of Harvard College Yeast cell expressing heterologous receptor kinase
EP0804575A1 (en) 1994-08-11 1997-11-05 Takeda Chemical Industries, Ltd. G protein coupled receptor protein, production, and use thereof
CA2135253A1 (en) 1994-11-07 1996-05-08 Michael Dennis Compound screening based on a window of chemical-messenger-independent activity
KR19990022531A (ko) * 1995-06-06 1999-03-25 벤슨 로버트 에이치. Ｇ-단백질 수용체 ｈｔｎａｄ２９
CA2232733A1 (en) 1995-09-20 1997-03-27 Orikkalapat Prem Das Yeast receptor and g-protein fusion protein
FR2742033B1 (fr) * 1995-12-08 1998-01-16 Achart Jacques Appareil pour l'ouverture de coquillages de mollusques bivalves
DE69637211T2 (de) 1995-12-11 2008-05-08 New England Medical Center Hospitals, Inc., Boston Test für und verwendungen von liganden von peptidhormonrezeptoren.
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US6399326B1 (en) 1996-07-02 2002-06-04 President And Fellows Of Harvard College Nucleic acids encoding neural/pancreatic receptor tyrosine phosphatase
EP0929691B1 (en) * 1996-09-24 2004-12-15 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
EP0948532A4 (en) 1996-12-27 2002-09-25 Merck & Co Inc GALANIN GALR2 RECEPTOR FROM THE MOUSE AND NUCLEOTIDES THAT ENCODE IT
US6403305B1 (en) 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
US6255089B1 (en) 1997-02-27 2001-07-03 Albany Medical College Constitutively activated serotonin receptors
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP0965041B1 (en) 1997-04-14 2009-02-18 Arena Pharmaceuticals, Inc. A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
US5891720A (en) 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
EP0878542A3 (en) 1997-04-22 2000-04-19 Smithkline Beecham Corporation cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor
AU7966098A (en) 1997-06-12 1998-12-30 Smithkline Beecham Corporation Hm74a receptor
US5955308A (en) 1997-06-18 1999-09-21 Smithkline Beecham Corporation cDNA clone HEAOD54 that encodes a human 7-transmembrane receptor
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
KR100629185B1 (ko) 1997-11-11 2006-09-28 오노 야꾸힝 고교 가부시키가이샤 인간 리조포스파티드산 수용체 물질 및 그 용도
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
ATE440865T1 (de) 1998-03-26 2009-09-15 Univ Leland Stanford Junior Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region
WO1999052927A1 (en) 1998-04-14 1999-10-21 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
JP2002521681A (ja) * 1998-07-31 2002-07-16 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 内因性の構成的に活性化されるｇタンパク質−共役オーファン受容体
CA2341154A1 (en) 1998-09-03 2000-03-16 Asahi Kasei Kabushiki Kaisha Novel receptor protein and method for the diagnosis of an inflammatory disease by using the same
WO2000022131A2 (en) 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
US20030229216A1 (en) * 1998-10-13 2003-12-11 Ruoping Chen Constitutively activated human G protein coupled receptors
CA2371821A1 (en) 1999-02-19 2000-08-24 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
EP1200474A1 (en) 1999-07-15 2002-05-02 Solvay Pharmaceuticals B.V. Human g-protein coupled receptor
EP1196572A1 (en) 1999-07-27 2002-04-17 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
JP2003510027A (ja) 1999-08-17 2003-03-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｐｇｐｃｒ−３ポリペプチドおよびそのｄｎａ配列
WO2001014577A1 (en) 1999-08-24 2001-03-01 Smithkline Beecham Corporation Molecular cloning of a galanin like 7tm receptor (axor40)
WO2001016159A1 (en) 1999-08-27 2001-03-08 Smithkline Beecham Corporation Gpcr, theant
GB9923889D0 (en) 1999-10-08 1999-12-08 Pfizer Ltd Novel polypeptide
GB9924951D0 (en) 1999-10-21 1999-12-22 Pfizer Ltd Novel polypeptide
WO2001031014A2 (en) 1999-10-27 2001-05-03 Pharmacia & Upjohn Company G protein-coupled receptors expressed in human brain
AU782959B2 (en) 1999-11-17 2005-09-15 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors

Also Published As

Publication number Publication date
EP1121431B9 (en) 2007-10-24
WO2000022129A9 (en) 2000-09-14
KR20010085911A (ko) 2001-09-07
AU2011200016A1 (en) 2011-01-27
JP2002527727A (ja) 2002-08-27
WO2000021987A9 (en) 2000-08-24
AU769987B2 (en) 2004-02-12
US6555339B1 (en) 2003-04-29
WO2000021987A2 (en) 2000-04-20
DK1121431T5 (da) 2008-03-03
DE1121431T1 (de) 2002-05-23
ATE318311T1 (de) 2006-03-15
AU2008200231A1 (en) 2008-02-07
IL141965A0 (en) 2002-03-10
DE69929993T4 (de) 2008-08-28
ES2163384T3 (es) 2006-12-01
IL141965A (en) 2008-08-07
CN1398298A (zh) 2003-02-19
KR100598752B1 (ko) 2006-07-11
CN1329511C (zh) 2007-08-01
ES2163384T1 (es) 2002-02-01
AU2004203102A1 (en) 2004-07-29
JP4672866B2 (ja) 2011-04-20
DK1121431T3 (da) 2006-06-26
EP1121431B1 (en) 2006-02-22
US7410777B2 (en) 2008-08-12
EP1121431A1 (en) 2001-08-08
AU6430799A (en) 2000-05-01
DE69929993T2 (de) 2006-10-26
JP2003531565A (ja) 2003-10-28
CA2342314A1 (en) 2000-04-20
WO2000022129A1 (en) 2000-04-20
AU2011200511A1 (en) 2011-03-03
AU2004203102B2 (en) 2007-10-18
WO2000021987A3 (en) 2000-07-13
DE69929993D1 (de) 2006-04-27
US20030105292A1 (en) 2003-06-05
JP4685241B2 (ja) 2011-05-18
NZ510331A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
IL141965A0 (en) Non-endogenous, constitutively activated human g protein-coupled receptors
ES2243095T3 (es) Receptores acoplados a proteina g humanos huerfanos.
Jüppner et al. The extracellular amino-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1-34)
Baud et al. EMR1, an unusual member in the family of hormone receptors with seven transmembrane segments
US5883075A (en) Cyclic endothelin antagonists
Bullock et al. Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists
Chen et al. Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species
EP0849361B1 (en) Novel ligands of the neuropeptide receptor HFGAN72
AU1769601A (en) Endogenous and non-endogenous versions of human G protein-coupled receptors
EP1007563A1 (en) Hm74a receptor
Blomenröhr et al. Differences in structure–function relations between nonmammalian and mammalian gonadotropin-releasing hormone receptors
ES2201061T3 (es) Genes de receptores opioides delta.
EP0552417B1 (en) Cyclic peptides and use thereof
Maiti et al. GnRH-II analogs for selective activation and inhibition of non-mammalian and type-II mammalian GnRH receptors
Mochizuki et al. Cloning and expression of the human 5-HT1B-type receptor gene
CA2330251A1 (en) Cloning and identification of the motilin receptor
DK0692026T3 (da) En human T-cellereceptor fra den G-proteinkoblede receptorfamilie
Koshimizu et al. Truncation of the receptor carboxyl terminus impairs membrane signaling but not ligand binding of human ETB endothelin receptor
Suva et al. Design, synthesis and utility of novel benzophenone-containing calcitonin analogs for photoaffinity labeling the calcitonin receptor
US7816492B2 (en) Human G protein-coupled receptors
US20130089549A1 (en) B cell activating factor antagonist and preparation method and use thereof
Waelbroeck et al. Binding of the labelled muscarinic toxin 125I-MT1 to rat brain muscarinic M1 receptors
US20050020492A1 (en) Melanin-concentrating hormone analogs
EP1140968A4 (en) HUMAN MELANOCORTIN-1 RECEPTOR PROTEIN DNA-MOLECULE-ENCODING SPLICE VERSIONS
Brauns et al. Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121012